Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M

Core Insights - Cosmos Health Inc. reported record financial results for Q3 2025, achieving the highest revenue, gross profit, and gross margin in its history, driven by strong performance across all core business segments [2][4][6] Financial Highlights - Q3 2025 revenue reached $17.11 million, a 38% increase from $12.41 million in Q3 2024, marking a new all-time high [4] - For the nine-month period ended September 30, 2025, revenue totaled $45.57 million, up 13% from $40.20 million in the prior-year period [4] - Gross profit for Q3 2025 increased 116% to $2.60 million, compared to $1.21 million in Q3 2024, the highest quarterly gross profit in the company's history [4] - Gross margin expanded to a record 15.21%, up from 9.72% a year earlier, reflecting improved efficiencies and a stronger sales mix [4] - Total operating expenses were $4.42 million in Q3 2025, compared to $3.45 million in Q3 2024, due to strategic investments in talent and new hires [4] Balance Sheet - Total assets increased to $69.49 million, up from $61.84 million as of June 30, 2025, reflecting enhanced liquidity and higher inventory levels [3][9] - Cash and cash equivalents rose sharply to $4.63 million from $0.66 million as of June 30, 2025, indicating significant improvement in financial flexibility [9] - Total liabilities increased to $46.36 million from $35.65 million as of June 30, 2025, due to the strategic utilization of a $300 million financing facility [9] Strategic Initiatives - The company secured a $300 million digital financing facility, enabling the build-up of a substantial digital assets portfolio and supporting long-term growth initiatives [6][9] - Cosmos Health is expanding its proprietary brands globally, including Sky Premium Life and C-Sept/C-Scrub, and has entered the U.S. market with local manufacturing [7][9] - The company signed a contract manufacturing agreement for the production of MYCOFAGYL pessaries, expanding its pharmaceutical portfolio into the gynecology segment [9]